Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes.
Transgenic mouse models with nicotinic acetylcholine receptor (nAChR) knockouts and knockins have provided important insights into the molecular substrates of addiction and disease. However, most studies of heterologously expressed neuronal nAChR have used clones obtained from other species, usually human or rat. In this work, we use mouse clones expressed in Xenopus oocytes to provide a relatively comprehensive characterization of the three primary classes of nAChR: muscle-type receptors, heteromeric neuronal receptors, and homomeric alpha7-type receptors. We evaluated the activation of these receptor subtypes with acetylcholine and cytisine-related compounds, including varenicline. We also characterized the activity of classic nAChR antagonists, confirming the utility of mecamylamine and dihydro-beta-erythroidine as selective antagonists in mouse models of alpha3beta4 and alpha4beta2 receptors, respectively. We also conducted an in-depth analysis of decamethonium and hexamethonium on muscle and neuronal receptor subtypes. Our data indicate that, as with receptors cloned from other species, pairwise expression of neuronal alpha and beta subunits in oocytes generates heterogeneous populations of receptors, most likely caused by variations in subunit stoichiometry. Coexpression of the mouse alpha5 subunit had varying effects, depending on the other subunits expressed. The properties of cytisine-related compounds are similar for mouse, rat, and human nAChR, except that varenicline produced greater residual inhibition of mouse alpha4beta2 receptors than with human receptors. We confirm that decamethonium is a partial agonist, selective for muscle-type receptors, but also note that it is a nondepolarizing antagonist for neuronal-type receptors. Hexamethonium was a relatively nonselective antagonist with mixed competitive and noncompetitive activity.
Papke
Roger L
RL
Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville, Florida 32610-0267, USA. rlpapke@ufl.edu
Wecker
Lynn
L
Stitzel
Jerry A
JA
D000109:Acetylcholine / Q000494:pharmacology; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001392:Azocines / Q000494:pharmacology; D001552:Benzazepines / Q000494:pharmacology; D003650:Decamethonium Compounds / Q000494:pharmacology; D004079:Dihydro-beta-Erythroidine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D015870:Gene Expression / Q000187:drug effects; D018738:Hexamethonium / Q000494:pharmacology; D006801:Humans; D008464:Mecamylamine / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic / Q000378:metabolism; D018482:Muscle, Skeletal / Q000378:metabolism*; D018733:Nicotinic Antagonists / Q000494:pharmacology; D009865:Oocytes / Q000378:metabolism*; D011807:Quinolizines / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D011978:Receptors, Nicotinic / Q000096:biosynthesis* / Q000502:physiology; D000068580:Varenicline; D014982:Xenopus laevis; D000093843:Quinolizidine Alkaloids
D000109:Acetylcholine; D000470:Alkaloids; D001392:Azocines; D001552:Benzazepines; D003650:Decamethonium Compounds; D004079:Dihydro-beta-Erythroidine; D018738:Hexamethonium; D008464:Mecamylamine; D018733:Nicotinic Antagonists; D011807:Quinolizines; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D000068580:Varenicline; C004712:cytisine; D000093843:Quinolizidine Alkaloids; C033019:decamethonium